HIGHLIGHT THERAPEUTICS
Highlight Therapeutics is a private, clinical-stage company dedicated to unlocking the full potential of immuno-oncology.
HIGHLIGHT THERAPEUTICS
Social Links:
Industry:
Biopharma Biotechnology Health Care Medical
Founded:
2010-01-01
Address:
Paterna, Comunidad Valenciana, Spain
Country:
Spain
Website Url:
http://www.highlighttherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
34 961 10 99 55
Email Addresses:
[email protected]
Total Funding:
27.05 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Content Delivery Network Euro Microsoft Exchange Online Organization Schema
Similar Organizations
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Akashi Therapeutics
Akashi Therapeutics is a clinical stage biopharmaceutical company.
GENFIT
GENFIT is a late-stage biopharmaceutical company.
Hope Medicine
Hope Medicine is a science-driven clinical stage biopharmaceutical company
Leap Therapeutics
Leap Therapeutics is a clinical-stage biopharmaceutical company.
MediPrint Ophthalmics
MediPrint Ophthalmics is a clinical stage eye care pharmaceutical company.
Mereo Biopharma
Mereo is a new UK-based speciality biopharmaceutical company.
Minerva Neuroscience
Minerva Neurosciences is a clinical-stage biopharmaceutical company
Molecular Partners
Molecular Partners is a clinical-stage biopharmaceutical company.
Ocugen
Ocugen is a clinical stage biopharmaceutical company.
Touchlight Genetics
Touchlight Genetics, a British bio-pharmaceutical company founded in 2007.
Current Advisors List
Current Employees Featured
Founder
Investors List
Centre for the Development of Industrial Technology (CDTI)
Centre for the Development of Industrial Technology (CDTI) investment in Venture Round - Highlight Therapeutics
Advent Life Sciences
Advent Life Sciences investment in Venture Round - Highlight Therapeutics
Columbus Venture Partners
Columbus Venture Partners investment in Venture Round - Highlight Therapeutics
Realiza Business Angels
Realiza Business Angels investment in Venture Round - Highlight Therapeutics
Realiza Business Angels
Realiza Business Angels investment in Venture Round - Highlight Therapeutics
Official Site Inspections
http://www.highlighttherapeutics.com Semrush global rank: 7.79 M Semrush visits lastest month: 437
- Host name: 35.0.153.160.host.secureserver.net
- IP address: 160.153.0.35
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Highlight Therapeutics"
Highlight Therapeutics - Crunchbase Company Profile & Funding
Organization. Highlight Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Contact Email …See details»
Contact - Highlight Therapeutics
Highlight Therapeutics, S.L. Parque Científico Universidad de Valencia Calle Catedrático Agustín Escardino, 9 Paterna 46980 (Valencia) Spain.See details»
Investors - Highlight Therapeutics
Highlight Therapeutics, S.L. Parque Científico Universidad de Valencia Calle Catedrático Agustín Escardino, 9 Paterna 46980 (Valencia) Spain.See details»
Highlight Therapeutics SL - LinkedIn
Highlight Therapeutics SL | 2,572 followers on LinkedIn. Unlocking the potential of immuno-oncology | Highlight, formerly known as Bioncotech Therapeutics S.L, is a private, clinical-stage company ...See details»
Highlight Therapeutics - PitchBook
Highlight Therapeutics General Information Description. Developer of RNA-based immuno-oncology therapies designed to combat cancer in patients. The company's therapies …See details»
Highlight Therapeutics - Company Profile - Tracxn
5 days ago Email ID: *****@highlighttherapeutics.com; Key Metrics. Total Funding. $27.1M in 2 rounds. Latest Funding Round. Series B, Feb 05, 2021, $27.1M. Investors. Advent Life …See details»
Highlight Therapeutics announces name change from
MADRID, Spain, April 17, 2020 (GLOBE NEWSWIRE) -- Highlight Therapeutics, a clinical-stage biopharmaceutical company developing RNA-based therapies...See details»
Highlight Therapeutics - Craft
Highlight Therapeutics (formerly Bioncotech) is a clinical-stage immune-oncology company. It develops RNA-based therapies against validated targets in cancer and immune cells.See details»
Highlight Therapeutics: BO-112 published in JITC - GlobeNewswire
Feb 12, 2021 Highlight Therapeutics S. L. [email protected]: Marisol Quintero, CEO Mo PR Advisory: Tel: +44 (0) 7876 444977 / 07860 361746: Mo Noonan/Jonathan BirtSee details»
Highlight Therapeutics: BO-112 published in JITC - Yahoo Finance
Dec 2, 2021 Intratumoral co-injection of BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy Pre-clinical study data follow publication of positive Phase 2 …See details»
Positive Phase 2b results in 2nd line melanoma - GlobeNewswire
Nov 12, 2021 Highlight Therapeutics S. L. [email protected]: Marisol Quintero, CEO Mo PR Advisory: Tel: +44 (0) 7876 444977 / 07860 361746: Mo Noonan/Jonathan BirtSee details»
Highlight Therapeutics to present data from Phase 2 …
Apr 13, 2021 Highlight Therapeutics S. L. [email protected] Marisol Quintero, CEO Mo PR Advisory Tel: +44 (0) 7876 444977 / 07860 361746 Mo Noonan/Jonathan Birt . 2 …See details»
Classes — Highlight Therapeutics
Highlight Therapeutics, S.L. Parque Científico Universidad de Valencia Calle Catedrático Agustín Escardino, 9 Paterna 46980 (Valencia) SpainSee details»
Highlight & Pivotal start Phase IIa melanoma trial - GlobeNewswire
Mar 2, 2021 [email protected]: Mo PR Advisory: Tel: +44 (0) 7876 444977 / 07860 361746: Mo Noonan/Jonathan Birt ...See details»
Highlight Therapeutics & Pivotal advance into a phase IIa to …
Oct 21, 2020 Trial will examine administration of Highlight’s BO-112 in combination with an anti-PD1 in patients with liver metastasis from colorectal or gastric/gastro-esophageal junction …See details»
News - Highlight Therapeutics
Highlight Therapeutics & Cima announce positive results from pre-clinical study combining BO112 + STING agonist published in Journal for ImmunoTherapy of CancerSee details»
Highlight Therapeutics to present at the American - GlobeNewswire
MADRID, Spain, March 15, 2022 (GLOBE NEWSWIRE) -- Highlight Therapeutics, ("Highlight"), a clinical-stage biopharmaceutical company developing RNA-based therapies against cancer, …See details»
Highlight Therapeutics and Pivotal work together on Melanoma …
Mar 2, 2021 Trial will examine administration of Highlight’s BO-112 in combination with an anti-PD1 in unresectable or metastatic melanoma patients Recruitment has already begun across …See details»
Highlight Therapeutics announces follow-up results from
Apr 13, 2022 Highlight Therapeutics S. L. [email protected]: Marisol Quintero, CEO Mo PR Advisory: Tel: +44 (0) 7876 444977 / 07860 361746: Mo Noonan/Jonathan BirtSee details»